We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ADVM market cap is 966.83M. The company's latest EPS is USD -1.1597 and P/E is -8.05.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 3.6M | 0 | 0 |
| Operating Income | -41.04M | -33.94M | -30.24M | -33.07M | -34.53M |
| Net Income | -40.13M | -32.74M | -29.06M | -31.51M | -32.89M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 250k | 0 | 7.5M | 0 | 3.6M |
| Operating Income | -68.55M | -117.95M | -146.12M | -157.14M | -123.99M |
| Net Income | -64.49M | -117.51M | -145.54M | -154.54M | -117.17M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 332.36M | 308.37M | 275.58M | 241.43M | 196.77M |
| Total Liabilities | 124.03M | 126.85M | 117.82M | 110.27M | 94.06M |
| Total Equity | 208.34M | 181.52M | 157.76M | 131.16M | 102.71M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 222.73M | 482.57M | 439.73M | 308.37M | 173.01M |
| Total Liabilities | 47.77M | 48.22M | 123.54M | 126.85M | 89.54M |
| Total Equity | 174.96M | 434.35M | 316.19M | 181.52M | 83.47M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -89.62M | -108.09M | -22.41M | -45.66M | -69.57M |
| Investing | 139.49M | 141.72M | 21.53M | 88.56M | 106.75M |
| Financing | 365k | 607k | N/A | 8k | -97k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -49.17M | -79.29M | -107.83M | -108.09M | -90.9M |
| Investing | -68.07M | -280.17M | 78.71M | 141.72M | 96.88M |
| Financing | 28.19M | 355.99M | 2.4M | 607k | 69k |
| Market Cap | 966.83M |
| Price to Earnings Ratio | -8.05 |
| Price to Sales Ratio | 262.36 |
| Price to Cash Ratio | 12.58 |
| Price to Book Ratio | 11.3 |
| Dividend Yield | - |
| Shares Outstanding | 101.03M |
| Average Volume (1 week) | 224.09k |
| Average Volume (1 Month) | 202.02k |
| 52 Week Change | 8.75% |
| 52 Week High | 29.80 |
| 52 Week Low | 7.10 |
| Spread (Intraday) | 2.48 (20.67%) |
| Company Name | Adverum Biotechnologies Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.adverum.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
